The concentrations of piperacillin in serum, bile, gallbladder wall, abdominal skeletal muscle, and adipose tissue were measured simultaneously at various times after the intravenous administration of a single 5-g dose to each of 14 patients undergoing biliary tract surgery. Piperacillin concentrated in the bile with peak levels exceeding 4,000 ,ug/ml. In a single patient with cystic duct obstruction, trace gallbladder bile piperacillin levels were measured. Gallbladder wall concentrations of piperacillin tended to be higher than corresponding serum concentrations, with a correlation observed between tissue values and the degree of acute gallbladder inflammation and gallbladder bile piperacillin concentrations. Mean peak muscle and adipose tissue piperacillin concentrations of 31 and 27 p.g/g, respectively, were reached at between 2 and 3 h after the start of infusion. These concentrations exceeded the minimum inhibitory concentration for a majority of susceptible organisms. A single 5-g dose of piperacillin achieved therapeutic levels in gallbladder wall, intraabdominal skeletal muscle, and adipose tissue and concentrated in the bile of patients with patent biliary tracts.
Piperacillin is a new semisynthetic penicillin derivative with activity against Pseudomonas aerugenosa, Enterobacteriaceae, and anaerobic organisms, including Bacteroides fragilis. Since it is more active against these organisms than is carbenicillin (3) and does not exhibit the toxicities associated with aminoglycoside therapy, it may play an important role in the treatment of abdominal infections. This Tisue and fluid handling. Blood samples were centrifuged at 1,200 x g for 5 min, and the serum was pipetted into empty collection tubes and frozen at -70°C until assayed. Common bile duct and gallbladder bile samples were immediately placed on ice, diluted 1:50 with 1% sodium phosphate buffer (pH 6), and frozen at -70°C.
Gallbladder, abdominal skeletal muscle, and adipose tissue samples were immediately placed on ice. All samples were trimmed of connective tissue and cut to a weight of approximately 0.5 g. They were blotted with sterile gauze, minced, and placed in a 15-mI Corningware tube on ice. Muscle and gallbladder tissue were homogenized in 1 to 2 ml of the phosphate buffer with a Tekmar Super Dispax homogenizer. Fat samples were sonicated in 1 to 2 ml of buffer with a Kontes microultrasonic cell disrupter. The exact tissue weight and buffer volume were recorded.
The homogenate and sonic extract were centrifuged in a Sorvall refrigerated centrifuge (model RC-2) at 16,000 rpm for 20 min. After centrifugation, the supernatant was removed, placed in empty collection tubes, and frozen at -70°C.
Assay procedure. Samples were assayed by using a previously described microbiological assay with Mi- (9) . Serum and bile standards and samples from patients were diluted one part serum or bile (known donors) to nine parts phosphate buffer. Tissue standards and samples were diluted one part abdominal skeletal muscle, adipose tissue, or gallbladder tissue supernatant to nine parts phosphate buffer. Tissue supernatant prepared from normal human cadaver tissue obtained within 24 h of death was used for the standard. Control assays verified that no antimicrobial activity was present in the diluent. Also, the effect of radiological dye was evaluated for possible effects on the test organism and was found to have no effect.
Data analysis. Concentrations of piperacillin in serum, bile, and tissue samples were adjusted for body weight, since a single 5-g dose was given to each patient. Tissue concentrations of the antibiotic were corrected for blood contamination by using spectrophotometric analysis to determine the hemoglobin concentration of the tissue supernatant. The amount of antibiotic contributed by blood was subtracted from the measured concentration of piperacillin in the tissue supernatant as described by Edberg and Sabath (4). The amount of drug contributed by blood was insignificant and ranged from 3 to 5% of the concentration. Since gallbladder mucosa was in contact with high concentrations of piperacillin in bile, the gallbladder tissue concentration of the drug was adjusted by using bilirubin as a marker. This amount was subtracted from the weight-and hemoglobin-adjusted concentration of piperacillin in gallbladder tissue. Bile piperacillin was variable and accounted for about 10o of gallbladder tissue piperacillin levels in most of our samples.
Since sampling times varied with each patient, the temporal relationship among the mean (± standard deviation) serum, abdominal skeletal muscle, and adipose tissue piperacillin concentrations was graphed. This was done by averaging the adjusted serum levels of the patients at 30-min intervals and plotting the linear regression line of these mean data points versus time. Abdominal skeletal muscle and adipose tissue concentrations were independently averaged at hourly intervals, and the mean values were plotted as a bar graph in relationship to the serum concentration-versus-time curve.
Multiple regression analysis (8) was used to assess the influence of piperacillin bile and blood levels and gallbladder tissue inflammation on piperacillin concentrations in gallbladder tissue. Gallbladder histology was independently assessed evaluated by two pathologists and rated on a four-point scale for degree of acute inflammation. In no case was there a discrepancy of more than one point in the histological grading.
RESULTS
Simultaneously obtained serum, bile, and tissue concentrations of piperacillin in 14 patients undergoing biliary tract surgery are presented in Table 1 . A graphic representation of the mean (± standard deviation) serum, abdominal skeletal muscle, and adipose tissue concentrations of piperacillin versus time is shown in Fig. 1 . Additional serum samples were drawn during the intraoperative period at times other than those mentioned in Table 1 . All of these data points were used to construct the graph. The disappearance half-life in serum was 1.7 h with a coefficient of determination (r2) of 0.86. The areas under the abdominal skeletal muscle and adipose tissue concentration-time curves were 25 and 16%, respectively, of the area under the serum concentration-time curve.
Piperacillin concentrated in the bile of patients with patent biliary ducts. The ratio of piperacillin levels in gallbladder bile or common duct bile to levels in serum was always greater than 1.0. Levels measured in bile during the first 3 h after administration were commonly more than 30 times higher than concentrations in simultaneously drawn serum. An impacted gallstone in the cystic duct was present in the only patient with a gallbladder bile-to-serum ratio of less than 1.0. The gallbladder bile piperacillin level for this patient was reported as trace, with a corresponding common bile duct level of 2,440 ,uglml. The mean gallbladder tissue piperacillin level (± standard deviation) was 177 ± 128 jxg/ml. In seven of nine patients from whom gallbladder tissue samples were taken, tissue piperacillin levels were equal to or greater than the simultaneously obtained blood levels. In the absence of any known active transport system to explain the higher levels in gallbladder tissue, a linear regression analysis was carried out to assess the influence of acute gallbladder tissue inflammation and the concentration of piperacillin in bile and serum on gallbladder tissue piperacillin levels. High correlations were found between tissue levels and bile levels (r = 0.76) and between tissue levels and the degree of acute tissue inflammation (r = 0.75). Knowledge of the piperacillin concentration in bile and the extent of tissue inflammation accounted for 58 and 56%, respectively, of the variability in gallbladder tissue levels. Serum piperacillin levels were not highly correlated with tissue levels and accounted for 13% of the variability observed. A forward (stepwise)-inclusion multiple regression analysis (where tissue piperacillin level was the dependent variable and bile and blood piperacillin levels and inflammation were the independent variables) was performed to assess the combined effects of these variables. Bile levels were entered into the equation first (R = 0.76), followed by inflammation (R = 0.83) and then blood levels (R = 0.84). Although R increased from 0.76 to 0.83 with the addition of inflammation to bile levels, this was not significant (F = 2.39; df = 1.6; P > 0.05). The increase in predictive power when blood levels were entered was negligible (change in R = 0.02). Weighting and combining these three variables in a mathematically optimal way did not increase our ability to predict tissue levels.
DISCUSSION
The results of this study showed that piperacillin achieved concentrations in abdominal skeletal muscle and adipose tissue that were high enough to be therapeutically active against a majority of susceptible bacteria after a single 5-g intravenous dose given at 30 to 60 min before surgery. Previous studies also have reported good tissue penetration by piperacillin after a single dose (1, 6). However, these studies have demonstrated maximum tissue levels within 1 h after piperacillin administration, whereas peak tissue levels in the present study occurred at 2 to 3 h after administration. These differences may be secondary to the physiological state of the tissue which is sampled (e.g., normal, traumatized, or scarred tissue) (1, 5, 6, 10). Any extrapolation of data to other tissues must carefully consider these conditions.
The fate of piperacillin in the biliary tract is similar to that of other beta-lactam antibiotics (2, 7) . In the presence of a patent ductal system, piperacillin was concentrated and the levels were very high. A subtherapeutic gallbladder bile piperacillin level was measured when the cystic duct was obstructed.
High gallbladder tissue levels of piperacillin in the absence of an active transport system capable of carrying a molecule as large as piperacillin (molecular weight, 540) caused us to assess the possibility that bile piperacillin levels or gallbladder tissue inflammation contributed to these findings. Although the number of tissue and bile samples available for evaluation permit only tentative conclusions, it appears that both may influence gallbladder tissue levels of this drug. Further study will be required to define their independent or combined influence on tissue levels. The low correlation between serum levels and gallbladder tissue levels should not be interpreted to mean that this source of piperacillin is insignificant to gallbladder tissue concentration. In the presence of cystic duct obstruction, serum may be the primary source of drug, as demonstrated in one patient in this study with obstruction who achieved high gallbladder tissue levels of piperacillin.
